Loading clinical trials...
Loading clinical trials...
Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma
Conditions
Interventions
RAD001
Locations
1
United States
M.D. Anderson Cancer Center
Houston, Texas, United States
Start Date
April 1, 2004
Primary Completion Date
September 1, 2006
Completion Date
September 1, 2006
Last Updated
April 27, 2025
NCT06735690
NCT05564390
NCT00131014
NCT06074666
NCT03050268
NCT06846671
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions